MOLAM: Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.
Study Details
Study Description
Brief Summary
Despite good initial response, some patients with core binding factor and/or NPM1-mutated AML eventually relapse. Some of these patients can be identified earlier on, before overt cytological relapse, when followed for minimal residual disease. The outcome of patients treated when molecular relapse is confirmed, before overt cytological relapse, is not well known. This multi-center retrospective will therefore study the outcome of these patients and try to specify the role of allogeneic stem cell transplantation in this setting.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Molecular relapse Confirmed molecular relapse, without overt cytological relapse |
Other: No intervention
Retrospective analysis
|
Cytological relapse Overt cytological relapse, without prior molecular relapse |
Other: No intervention
Retrospective analysis
|
Persistent responders No molecular or cytological relapse during follow-up |
Other: No intervention
Retrospective analysis
|
Outcome Measures
Primary Outcome Measures
- Event-free survival [Up to 5 years]
Secondary Outcome Measures
- Overall survival [Up to 5 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients between 18 and 61 years
-
Diagnosis between 2010 and 2019
-
Core binding factor and/or NPM1 acute myeloid leukemia
-
First complete remission after induction therapy
-
Measurable residual disease measurement after end of consolidation therapy
Exclusion Criteria:
-
Acute promyelocytic leukemia
-
Allogeneic stem cell transplantation in CR1
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Angers University Hospital | Angers | France |
Sponsors and Collaborators
- University Hospital, Angers
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 202100042